Disease · MONDO_0005404
Trials25
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
1 to 20 of 25
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00375973 | Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome | Phase 2/3 | 60 | 2015-07-27 | Fatigue Syndrome, Chronic | DULOXETINE | Its record names the disease | ClinicalTrials.gov |
| NCT04141696 | A Proof-of-Concept Trial on the Effect of Ketamine on Fatigue | Phase 1/2 | 10 | 2025-04-15 | Fatigue | KETAMINE | Its record names the disease | ClinicalTrials.gov |
| NCT00977171 | Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome | Phase 2 | 3 | 2014-06-09 | Chronic Fatigue Syndrome, Orthostatic Hypotension, Neurally Mediated Hypotension, Neurogenic Orthostatic Hypotension | DROXIDOPA | Its record names the disease | ClinicalTrials.gov |
| NCT00215800 | The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome | Phase 3 | 234 | Chronic Fatigue Syndrome, Myalgic Encephalomyelitis | RINTATOLIMOD | Its record names the disease | ClinicalTrials.gov | |
| NCT00580619 | Autonomic Nervous System and Chronic Fatigue Syndrome | Phase 1 | 170 | Chronic Fatigue Syndrome, Orthostatic Intolerance, Postural Tachycardia Syndrome | METHYLDOPA, TILARGININE, TRIMETHAPHAN | Its record names the disease | ClinicalTrials.gov | |
| NCT06366724 | LIFT: Life Improvement Trial | Phase 2 | 160 | ME/CFS, Long COVID, PASC | NALTREXONE, PYRIDOSTIGMINE | Its record names the disease | ClinicalTrials.gov | |
| NCT02229942 | B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study. | Phase 3 | 151 | Chronic Fatigue Syndrome/ Myalgic Encephalitis (CFS/ME) | RITUXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT01518634 | Imipramine Treatment for Patients With Multi-organ Bodily Distress Syndrome | Phase 2 | 138 | Somatisation Disorder, Somatoform Disorders | IMIPRAMINE | Its record names the disease | ClinicalTrials.gov | |
| NCT01966276 | The Synergy Trial: Methylphenidate Plus a CFS-Specific Nutrient Formula as a Treatment for Chronic Fatigue Syndrome | Phase 2 | 134 | Chronic Fatigue Syndrome (CFS), Myalgic Encephalomyelitis (ME) | METHYLPHENIDATE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT01040429 | The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial | Phase 2 | 120 | Chronic Fatigue Syndrome, Myalgic Encephalomyelitis | CLONIDINE | Its record names the disease | ClinicalTrials.gov | |
| NCT07285473 | Low-Dose Naltrexone For ME/CFS: Dose-Finding | Phase 2 | 75 | Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | NALTREXONE | Its record names the disease | ClinicalTrials.gov | |
| NCT01154647 | Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes | Not applicable | 70 | Fatigue Syndrome, Chronic, Fibromyalgia, Arthritis, Rheumatoid | CITALOPRAM | Its record names the disease | ClinicalTrials.gov | |
| NCT02108210 | Cytokine Inhibition in Chronic Fatigue Syndrome Patients | Phase 2/3 | 50 | Chronic Fatigue Syndrome | ANAKINRA | Its record names the disease | ClinicalTrials.gov | |
| NCT02517151 | Iron Supplementation in Inflammatory Bowel Disease (IBD) Patients With Chronic Fatigue | Phase 2 | 36 | Chronic Fatigue, Inflammatory Bowel Disease | FERRIC CARBOXYMALTOSE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00478465 | Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV) | Phase 1/2 | 30 | Chronic Fatigue Syndrome | VALGANCICLOVIR | Its record names the disease | ClinicalTrials.gov | |
| NCT00848692 | Drug Intervention in Chronic Fatigue Syndrome | Phase 2/3 | 30 | Chronic Fatigue Syndrome | RITUXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT01156909 | B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome | Phase 2 | 29 | Chronic Fatigue Syndrome, Myalgic Encephalomyelitis | RITUXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT05967052 | Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitation | Phase 2 | 23 | Chronic Fatigue Syndrome, COVID-19, Long Haul | PREGABALIN | Its record names the disease | ClinicalTrials.gov | |
| NCT06147050 | Effect of Metformin in Reducing Fatigue in Long COVID in Adolescents | Phase 3 | 16 | Long COVID | METFORMIN | Its record names the disease | ClinicalTrials.gov | |
| NCT01156922 | B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome | Phase 2 | 8 | Chronic Fatigue Syndrome, Myalgic Encephalomyelitis | RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005404/trials